Paper407012
Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
Cumber AJ and 1 other. Chem Biol Interact, 1977. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Papers, record 407012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/407012
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Altretamine | Major topic |
| Triazines | Major topic |
| Animals | |
| Humans | |
| Lung Neoplasms | |
| Mice | |
| Neoplasm Transplantation | |
| Neoplasms, Experimental | |
| Plasmacytoma | |
| Solubility | |
| Structure-Activity Relationship | |
| Transplantation, Heterologous |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7656502 | Clinical pharmacokinetics of altretamine. | Clin Pharmacokinet | 1995 | https://conductscience.org/library/papers/7656502 | PubMed |
| 7272193 | British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7272193 | PubMed |
| 6808457 | Hexamethylmelamine and hexamethylmelamine hydrochloride. | Pharm Weekbl Sci | 1982 | https://conductscience.org/library/papers/6808457 | PubMed |
| 6807560 | The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6807560 | PubMed |
| 6401427 | Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6401427 | PubMed |
| 3098444 | Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3098444 | PubMed |
| 3091280 | Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3091280 | PubMed |
| 3087399 | Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3087399 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/407012
GET https://conductscience.org/api/papers/v1/407012/authors